Health insurer Centene has received regulatory approval from the New York Attorney General for its Fidelis Care transaction valued at around $3.75 billion.
Earlier in April, the company received approvals from the New York Department of Health and the New York Department of Financial Services.
Centene said it now expects to close the transaction on or about July 1, 2018. Upon completion, Fidelis Care will become Centene's health plan in New York State.
"With this regulatory approval, we have a clear path to completing our transaction with Fidelis Care and expanding Centene's national leadership in government sponsored healthcare," said Michael Neidorff, chairman and CEO of Centene Corporation.
"We have been hard at work planning for the seamless integration of Fidelis Care and its members into the Centene network. Upon completion, we look forward to delivering on the opportunities this transaction will create for all of our stakeholders by enabling us to transform health in the New York community, one person at a time."
Health Insurance, Centene, Michael Neidorff, US